Moomoo AI 已提取核心信息
Bristol-Myers Squibb Company (BMS), through its subsidiary Rudolph Merger Sub Inc., has announced a tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash. The offer is part of a definitive merger agreement aimed at acquiring the entire equity interest in RayzeBio, making it a wholly owned subsidiary of BMS. The tender offer is subject to customary conditions, including the receipt of a majority of RayzeBio's shares and regulatory approvals. The offer, dated January 25, 2024, is not contingent on financing. BMS plans to finance the acquisition through cash on hand, debt issuance, or borrowing. The merger is expected to follow promptly after the tender offer's completion, subject to the satisfaction of remaining conditions. RayzeBio specializes in radiopharmaceutical therapeutics, with its lead program in Phase 3 clinical trials. The acquisition aligns with BMS's strategic focus on innovative medicines for serious diseases.
Bristol-Myers Squibb Company (BMS), through its subsidiary Rudolph Merger Sub Inc., has announced a tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash. The offer is part of a definitive merger agreement aimed at acquiring the entire equity interest in RayzeBio, making it a wholly owned subsidiary of BMS. The tender offer is subject to customary conditions, including the receipt of a majority of RayzeBio's shares and regulatory approvals. The offer, dated January 25, 2024, is not contingent on financing. BMS plans to finance the acquisition through cash on hand, debt issuance, or borrowing. The merger is expected to follow promptly after the tender offer's completion, subject to the satisfaction of remaining conditions. RayzeBio specializes in radiopharmaceutical therapeutics, with its lead program in Phase 3 clinical trials. The acquisition aligns with BMS's strategic focus on innovative medicines for serious diseases.
百时美施贵宝公司（BMS）通过其子公司Rudolph Merger Sub Inc. 宣布要约收购RayzeBio, Inc.的所有已发行股份，以每股62.50美元的现金收购RayzeBio, Inc.的所有已发行股份。该要约是最终合并协议的一部分，该协议旨在收购RayzeBio的全部股权，使其成为BMS的全资子公司。要约要约受惯例条件的约束，包括获得RayzeBio的大部分股票和监管部门的批准。该报价的日期为2024年1月25日，不以融资为条件。BMS计划通过手头现金、债务发行或借款为收购融资。合并预计将在要约完成后立即进行，但须满足其余条件。RayzeBio专门研究放射性药物疗法，其主导项目是3期临床试验。此次收购符合BMS对治疗严重疾病的创新药物的战略重视。
百时美施贵宝公司（BMS）通过其子公司Rudolph Merger Sub Inc. 宣布要约收购RayzeBio, Inc.的所有已发行股份，以每股62.50美元的现金收购RayzeBio, Inc.的所有已发行股份。该要约是最终合并协议的一部分，该协议旨在收购RayzeBio的全部股权，使其成为BMS的全资子公司。要约要约受惯例条件的约束，包括获得RayzeBio的大部分股票和监管部门的批准。该报价的日期为2024年1月25日，不以融资为条件。BMS计划通过手头现金、债务发行或借款为收购融资。合并预计将在要约完成后立即进行，但须满足其余条件。RayzeBio专门研究放射性药物疗法，其主导项目是3期临床试验。此次收购符合BMS对治疗严重疾病的创新药物的战略重视。
有用
没用